Skip to main content
. 2025 Jul 11;16(11):3283–3295. doi: 10.7150/jca.113578

Figure 2.

Figure 2

Diallyl trisulfide synergistically enhances doxorubicin cytotoxicity in breast cancer cells. (A and B) Breast cancer cells—(A) MCF7 and (B) MDA-MB-231—were treated with the indicated concentrations of DOX for 24 and 48 hours, followed by MTT cell viability assay. (C and D) Breast cancer cells — (C) MCF7 and (D) MDA-MB-231— were treated with the indicated concentrations of DATS for 24 and 48 hours, followed by the MTT cell viability assay. (E and F) Breast cancer cells— (E) MCF7 and (F) MDA-MB-231—were pre-treated with Dox (0.5 and 1 µM) for 24 hours, followed by the addition of DATS (50 and 100 µM) for a combined treatment period of 48 hours, followed by MTT cell viability assay. (G and H) Combination index (CI) calculation in (G) MCF7 and (H) MDA-MB-231 cells. The CI reflects the degree of drug-drug interactions; in this study, CIs <0.9 indicated synergism, CIs ranging from 0.9 to 1.1 indicated additive effects, and CIs >1.1 indicated antagonistic effects. These results are expressed as a percentage of viable cells from treated groups compared with control cells, ns= not significant, *P < 0.05, **P < 0.01, ***P < 0.001.